http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Pre-Open Stock Movers 02/10: (TLRY) (GMDA) (CMLF) Higher; (VNRX) (CPST) (XONE) Lower (more...)
-
Gamida Cell Ltd. (GMDA) Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
-
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR
-
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
-
Gamida Cell to Present at Upcoming January Investor Conferences
-
Gamida Cell Added to NASDAQ Biotechnology Index
-
Gamida Cell (GMDA) Provides Regulatory Update on BLA for Omidubicel
-
Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
-
Gamida Cell (GMDA) Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel
-
Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission by End of 2020
-
Gamida Cell Presents Updated, Expanded Results from Phase 1 Study of Natural Killer Cell Therapy GDA-201 at ASH Annual Meeting and Exposition
-
Gamida Cell to Host Virtual Pipeline Deep Dive
-
Gamida Cell to Present at Upcoming Conferences
-
Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update
-
Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting
-
Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference
-
Gamida Cell Announces the Date of Its Third Quarter 2020 Financial Results and Webcast
-
Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration
-
Gamida Cell to Present at 2020 Virtual Cell & Gene Meeting on the Mesa
-
Gamida Cell Ltd. (GMDA) Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies Met all Three of its Secondary Endpoints
-
Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
-
Gamida Cell Presents Analysis of Observational Data Demonstrating the Impact of Donor Age in Hematopoietic Stem Cell Transplant Outcomes at the Virtual Cord Blood Connect Meeting
-
Gamida Cell to Participate in Upcoming Investor Conferences
-
Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September
-
Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration

